Logo image of MBX

MBX BIOSCIENCES INC (MBX) Stock Fundamental Analysis

NASDAQ:MBX - Nasdaq - US55287L1017 - Currency: USD

10.88  -0.95 (-8.03%)

After market: 10.88 0 (0%)

Fundamental Rating

3

MBX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for MBX as it has an excellent financial health rating, but there are worries on the profitability. MBX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MBX had negative earnings in the past year.
MBX Yearly Net Income VS EBIT VS OCF VS FCFMBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -10M -20M -30M

1.2 Ratios

MBX has a Return On Assets (-27.94%) which is in line with its industry peers.
The Return On Equity of MBX (-29.07%) is better than 66.49% of its industry peers.
Industry RankSector Rank
ROA -27.94%
ROE -29.07%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBX Yearly ROA, ROE, ROICMBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBX Yearly Profit, Operating, Gross MarginsMBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, MBX has about the same amount of shares outstanding.
There is no outstanding debt for MBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MBX Yearly Shares OutstandingMBX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M
MBX Yearly Total Debt VS Total AssetsMBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 20M 40M 60M 80M

2.2 Solvency

MBX has an Altman-Z score of 19.33. This indicates that MBX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.33, MBX belongs to the top of the industry, outperforming 91.35% of the companies in the same industry.
There is no outstanding debt for MBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.33
ROIC/WACCN/A
WACCN/A
MBX Yearly LT Debt VS Equity VS FCFMBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 25.75 indicates that MBX has no problem at all paying its short term obligations.
MBX has a Current ratio of 25.75. This is amongst the best in the industry. MBX outperforms 95.14% of its industry peers.
A Quick Ratio of 25.75 indicates that MBX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 25.75, MBX belongs to the top of the industry, outperforming 95.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 25.75
Quick Ratio 25.75
MBX Yearly Current Assets VS Current LiabilitesMBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for MBX have decreased strongly by -24.39% in the last year.
EPS 1Y (TTM)-24.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MBX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -34.82% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1033.77%
EPS Next 2Y-52.06%
EPS Next 3Y-34.82%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBX Yearly Revenue VS EstimatesMBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026
MBX Yearly EPS VS EstimatesMBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
Also next year MBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBX Price Earnings VS Forward Price EarningsMBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX Per share dataMBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as MBX's earnings are expected to decrease with -34.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.06%
EPS Next 3Y-34.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MBX BIOSCIENCES INC

NASDAQ:MBX (2/21/2025, 8:00:01 PM)

After market: 10.88 0 (0%)

10.88

-0.95 (-8.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners69.31%
Inst Owner Change26.77%
Ins Owners3.24%
Ins Owner Change97.97%
Market Cap363.61M
Analysts87.5
Price Target37.99 (249.17%)
Short Float %12.42%
Short Ratio8.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.99%
EPS NQ rev (3m)1.99%
EPS NY rev (1m)13.85%
EPS NY rev (3m)0.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-2.46
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS8.12
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.94%
ROE -29.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.75
Quick Ratio 25.75
Altman-Z 19.33
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-1033.77%
EPS Next 2Y-52.06%
EPS Next 3Y-34.82%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-101.06%
EBIT Next 3Y-48.66%
EBIT Next 5YN/A
FCF growth 1Y-36.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.3%
OCF growth 3YN/A
OCF growth 5YN/A